DMRA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026
Revenue
0
0
0
Cost of Revenue
0
0
0
Gross Profit
0
0
0
Operating Expenses
36.9M
+5.3%
35.0M
+13.6%
30.8M
R&D
25.5M
-0.3%
25.5M
+7.4%
23.8M
SG&A
11.4M
+20.5%
9.5M
+34.4%
7.0M
Operating Income
-36863000
-5.3%
-34994000
-13.6%
-30811000
EBITDA
-36858000
-5.3%
-34988000
-13.6%
-30806000
Net Income
-31991000
-2.6%
-31174000
-12.2%
-27783000
EPS (Basic)
$-0.40
-2.6%
$-0.39
+37.1%
$-0.62
EPS (Diluted)
$-0.40
-2.6%
$-0.39
+37.1%
$-0.62
Shares (Diluted)
61.8M
+1.1%
61.1M
+78.2%
34.3M
Damora Therapeutics (DMRA) — Financials